Aspira Women's Health says ARPA-H terminated $10M ENDOinform contract after receiving $3.5M

Aspira Women's Health Inc.

ARPA-H terminated $10M contract for ENDOinform test on June 9, 2025, citing unmet Milestone 3 specs.
Aspira had received $2M and $1.5M milestone payments (Nov 2024, Mar 2025) totaling $3.5M.
Company disputes termination, claims it met all Milestone 3 requirements and was progressing on Milestone 4.
CEO says R&D team will continue ENDOinform development targeting 2026 completion with shareholder and partner support.
Contract termination may accelerate development pace due to reduced administrative burden.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.